Kalaris and AlloVir Secure Stockholder Approval for Merger

Kalaris Therapeutics, a biopharmaceutical company concentrating on retina disease treatments, and AlloVir, a T cell immunotherapy firm, have announced the approval of their merger by AlloVir's stockholders. The approval was secured during a special stockholder meeting on March 12, 2025. Following the completion of customary closing conditions, the merged entity will operate under the Kalaris Therapeutics name and will trade on Nasdaq as KLRS. The merger comes with forward-looking stipulations, including potential risks in conditions to close, management of operating expenses, potential changes in stock ownership due to exchange ratio adjustments, and possible delays in product candidate developments. These forward-looking projections are subject to uncertainties involving clinical outcomes, regulatory approvals, and financial resources. As both companies navigate litigation and competitive challenges, they aim to leverage the merger to enhance their future financial and operational outcomes.